Content about Supreme Court

June 25, 2013

The healthcare industry continues to prepare for ACA implementation and the expected influx of newly eligible patients, said Emdeon's Kevin Mahoney. Many pharmacies are changing their staffing models in preparation for customers with expanded Medicaid benefits — especially as we approach the New Year. This is a good time for me to remind you to be thinking about your eligibility program.

In January, I offered Drug Store News readers a look at the pharmacy and technology trends facing our industry for the year. Here we are in June (can you believe it?), so I thought we should have a progress check and update for the back half of 2013.

February 3, 2014

The Generic Pharmaceutical Association on Monday identified its key priorities for 2014 — guarding against confusion a proposed labeling change would cause; gaining access to biosimilar generics; and heralding the cost savings generated by generic utilization.

WASHINGTON — The Generic Pharmaceutical Association on Monday identified its key priorities for 2014 — guarding against confusion a proposed labeling change would cause; gaining access to biosimilar generics; and heralding the cost savings generated by generic utilization. 

November 22, 2013

Canadian pharmacy retailer Shoppers Drug Mart has announced that the Supreme Court of Canada has upheld the Dec. 23, 2011, decision of the Court of Appeal of Ontario that restored the prohibition on private-label generic drug products in the Province of Ontario, which was subsequent to a decision of the Ontario Divisional Court dated Feb. 3, 2011, that declared the regulatory restrictions in respect of private-label generic drug products to be invalid.

TORONTO — Canadian pharmacy retailer Shoppers Drug Mart has announced that the Supreme Court of Canada has upheld the Dec. 23, 2011, decision of the Court of Appeal of Ontario that restored the prohibition on private-label generic drug products in the Province of Ontario, which was subsequent to a decision of the Ontario Divisional Court dated Feb. 3, 2011, that declared the regulatory restrictions in respect of private-label generic drug products to be invalid.

September 20, 2013

Only half of the uninsured Americans expected to gain health coverage next year will do so due to a Supreme Court decision that allows states to decide individually whether to expand Medicaid coverage to the poor under the Patient Protection and Affordable Care Act, according to published reports.

NEW YORK – Only half of the uninsured Americans expected to gain health coverage next year will do so due to a Supreme Court decision that allows states to decide individually whether to expand Medicaid coverage to the poor under the Patient Protection and Affordable Care Act, according to published reports.

August 8, 2013

The Supreme Court usually has a lot on its plate in any given year, but this year's term included a pretty big case for the pharmaceutical industry: the Federal Trade Commission v. Actavis, which concerned legal settlements between branded and generic drug makers that often occur when the latter attempts to market a generic drug before the former's patents have expired.

The Supreme Court usually has a lot on its plate in any given year, but this year's term included a pretty big case for the pharmaceutical industry: the Federal Trade Commission v. Actavis, which concerned legal settlements between branded and generic drug makers that often occur when the latter attempts to market a generic drug before the former's patents have expired.

June 24, 2013

Generic drug makers cannot be held liable if patients suffer harmful side effects after taking their drugs, the Supreme Court has ruled in a 5-4 decision.

WASHINGTON — Generic drug makers cannot be held liable if patients suffer harmful side effects after taking their drugs, the Supreme Court has ruled in a 5-4 decision.

June 18, 2013

Half a loaf, the saying goes, is better than none. For the generic drug industry, that means that the Supreme Court handed it a partial victory Monday by ruling that “pay for delay” patent settlements between brand name and generic drug companies aren’t necessarily illegal and should be considered on a case-by-case, “rule of reason” approach by the Federal Trade Commission, which staunchly opposes the practice.

Half a loaf, the saying goes, is better than none. For the generic drug industry, that means that the Supreme Court handed it a partial victory Monday by ruling that “pay for delay” patent settlements between brand name and generic drug companies aren’t necessarily illegal and should be considered on a case-by-case, “rule of reason” approach by the Federal Trade Commission, which staunchly opposes the practice.

June 17, 2013

Patent settlements between brand and generic drug makers commonly referred to as "pay-for-delay" settlements are not necessarily against the law, the Supreme Court ruled Monday.

NEW YORK — Patent settlements between brand and generic drug makers commonly referred to as "pay-for-delay" settlements are not necessarily against the law, the Supreme Court ruled Monday.

May 30, 2013

This summer, the Supreme Court will decide on a case that could determine whether generic drug makers can be held liable when patients suffer harmful side effects from taking their drugs.

This summer, the Supreme Court will decide on a case that could determine whether generic drug makers can be held liable when patients suffer harmful side effects from taking their drugs.

May 30, 2013

The year is only halfway done, but 2013 is already proving to be a year of particular importance for generic drugs as the industry awaits two important decisions from the Supreme Court and continues to wait for federal biosimilar regulations while fending off efforts to limit the scope of their use at the state level.

The year is only halfway done, but 2013 is already proving to be a year of particular importance for generic drugs as the industry awaits two important decisions from the Supreme Court and continues to wait for federal biosimilar regulations while fending off efforts to limit the scope of their use at the state level.

April 21, 2013

Last month, the Supreme Court heard Federal Trade Commission v. Actavis, which could impact the future of the generic drug industry at a time when 80% of all prescriptions dispensed in the United States are generic.

Last month, the Supreme Court heard Federal Trade Commission v. Actavis, which could impact the future of the generic drug industry at a time when 80% of all prescriptions dispensed in the United States are generic.

April 1, 2013

Just a week after the Supreme Court heard the Federal Trade Commission's lawsuit over its deal with AbbVie to sell a generic version of a testosterone-replacement therapy, Actavis is challenging the patent on another strength of the drug.

PARSIPPANY, N.J. — Just a week after the Supreme Court heard the Federal Trade Commission's lawsuit over its deal with AbbVie to sell a generic version of a testosterone-replacement therapy, Actavis is challenging the patent on another strength of the drug.

Actavis said Monday that it had filed with the Food and Drug Administration for approval of testosterone gel in the 1.62% strength. The drug is a generic version of AbbVie's AndroGel 1.62%. The case that went before the Supreme Court on March 25 concerns the 1% strength of AndroGel.

March 25, 2013

The Supreme Court heard arguments Monday in a case that could determine the future of generic drugs in America.

NEW YORK — The Supreme Court heard arguments Monday in a case that could determine the future of generic drugs in America.

The case, Federal Trade Commission v. Actavis, marks the latest attempt by federal authorities to put an end to what they say are deals between branded and generic drug companies that delay release of generic drugs to consumers.

March 19, 2013

The question of whether a generic drug company can be held liable for harmful side effects from its medicines goes before the Supreme Court Tuesday in a case involving a New Hampshire woman who sustained several injuries after taking a generic pain drug.

WASHINGTON — The question of whether a generic drug company can be held liable for harmful side effects from its medicines goes before the Supreme Court Tuesday in a case involving a New Hampshire woman who sustained several injuries after taking a generic pain drug.

March 5, 2013

The stakes are high in a case involving generic drug maker Actavis and the Federal Trade Commission that will soon go before the Supreme Court, the head of a generic drug industry lobbying group said in a conference call with reporters Tuesday.

NEW YORK — The stakes are high in a case involving generic drug maker Actavis and the Federal Trade Commission that will soon go before the Supreme Court, the head of a generic drug industry lobbying group said in a conference call with reporters Tuesday.

The case, FTC v. Actavis, will go before the high court on March 25 and may decide the future of patent settlements between branded and generic drug companies. The Generic Pharmaceutical Association filed an amicus brief with the court last week defending the settlements as beneficial to consumers.

March 1, 2013

The Supreme Court will hear arguments later this month in a case that could determine the future of many patent settlements between brand and generic drug makers.

WASHINGTON — The Supreme Court will hear arguments later this month in a case that could determine the future of many patent settlements between brand and generic drug makers.

The high court will hear arguments in the case, Federal Trade Commission v. Actavis, on March 25. The case was originally titled FTC v. Watson, but has changed since Watson Pharmaceuticals changed its name following its acquisition of Swiss generic drug maker Actavis.

February 28, 2013

Alabama's Supreme Court ruled in January that brand-name drug companies could be sued if patients suffer complications from generic versions of their medicines, according to published reports.

Alabama's Supreme Court ruled in January that brand-name drug companies could be sued if patients suffer complications from generic versions of their medicines, according to published reports. According to the New York Times, an Alabama man named Danny Weeks claimed he developed tardive dyskinesia after taking generic versions of Pfizer's acid reflux drug Reglan (metoclopramide). Pfizer acquired rights to the drug when it bought Wyeth in 2009, and generic drug makers Teva and Actavis, now owned by Watson, make generic versions.

January 29, 2013

In an effort to quell the significant sway creditors wield in dictating terms with retail vendors, the National Community Pharmacists Association, the National Grocers Association and the National Association of Convenience Stores on Monday submitted a joint brief to the Supreme Court as amici curiae in the case of American Express vs. Italian Colors Restaurant.

ALEXANDRIA, Va. — In an effort to quell the significant sway creditors wield in dictating terms with retail vendors, the National Community Pharmacists Association, the National Grocers Association and the National Association of Convenience Stores on Monday submitted a joint brief to the Supreme Court as amici curiae, or "friends of the court," in the case of American Express vs. Italian Colors Restaurant. 

January 28, 2013

Health care is evolving. As obvious of a statement as that is, it doesn’t change the fact that it is very real. Throughout last year, there was intense discussion on the Patient Protection and Affordable Care Act and what impact the outcome of the presidential election might have on its future. Now that the Supreme Court has ruled and elections are settled, healthcare companies and providers across the country are implementing strategies to meet ACA requirements.

Health care is evolving. As obvious of a statement as that is, it doesn’t change the fact that it is very real. Throughout last year, there was intense discussion on the Patient Protection and Affordable Care Act and what impact the outcome of the presidential election might have on its future. Now that the Supreme Court has ruled and elections are settled, healthcare companies and providers across the country are implementing strategies to meet ACA requirements.

January 15, 2013

Drug maker Otsuka Pharmaceuticals can keep generic versions of its schizophrenia drug off the market, according to published reports.

NEW YORK — Drug maker Otsuka Pharmaceuticals can keep generic versions of its schizophrenia drug off the market, according to published reports.

Bloomberg reported that the Supreme Court upheld a ruling that allowed Otsuka to block Canadian generic drug maker Apotex from marketing a version of the antipsychotic Abilify (aripiprazole), which Otsuka co-markets with Bristol-Myers Squibb.

December 11, 2012

The Supreme Court will review settlements between branded and generic drug companies that critics say delay patients' access to cheaper drug treatments, according to published reports.

NEW YORK — The Supreme Court will review settlements between branded and generic drug companies that critics say delay patients' access to cheaper drug treatments, according to published reports.

Politico reported that the justices had agreed to hear three cases, including Federal Trade Commission v. Watson Pharmaceuticals, involving settlements between branded and generic drug companies that critics deride as "pay-for-delay" deals.

November 14, 2012

Unilever’s Simple facial skin care brand has teamed up with AOL to announce the winners of a nationwide search for extraordinary women driving positive change in their communities.

NEW YORK — Unilever’s Simple facial skin care brand has teamed up with AOL to announce the winners of a nationwide search for extraordinary women driving positive change in their communities. The search is an extension of Makers, a multiplatform video experience that honors trailblazing women, including Sandra Day O’Connor, Hillary Clinton and Diane Von Furstenberg.

October 12, 2012

The Food and Drug Administration took the Family Smoking Prevention and Tobacco Control Act of 2009 one step closer to being considered by the Supreme Court earlier this week.

 SILVER SPRING, Md. — The Food and Drug Administration took the Family Smoking Prevention and Tobacco Control Act of 2009 one step closer to being considered by the Supreme Court earlier this week. The FDA recently petitioned the D.C. Circuit Court of Appeals to revisit the court's August decision that ruled in favor of the tobacco industry and precluded the FDA from mandating that graphic images depicting the consequences of smoking be placed on all cigarette packaging. 

September 18, 2012

As of Sept. 15, California became the eighth state in which Amazon.com will levy sales taxes on purchases made by residents in that state. Pennsylvania joined that group two weeks prior. Add to that the five states that don’t have any sales taxes, and that’s 13 states where national brick-and-click retailers are competing on a level playing field with the pure-play online retail juggernaut. 


As of Sept. 15, California became the eighth state in which Amazon.com will levy sales taxes on purchases made by residents in that state. Pennsylvania joined that group two weeks prior. Add to that the five states that don’t have any sales taxes, and that’s 13 states where national brick-and-click retailers are competing on a level playing field with the pure-play online retail juggernaut. 


August 30, 2012

Canadian pharmacy retailer Shoppers Drug Mart announced on Thursday that the Supreme Court of Canada has granted its application for leave to appeal to Ontario’s ban on private-label generic drugs.

TORONTO — Canadian pharmacy retailer Shoppers Drug Mart announced on Thursday that the Supreme Court of Canada has granted its application for leave to appeal to Ontario’s ban on private-label generic drugs.

“The company respects the decision of the Supreme Court of Canada and is pleased with the outcome,” the retailer stated. A hearing date has not yet been set, and no further details were provided.

According to Reuters, Canada’s Katz Group also has been granted leave to challenge the ban.